Basket | Login | Register

 
 
 
 

Phase III trials

Clinical Trials Watch

This section contains information about clinical trials that are:

  • Currently recruiting participants
  • Conducted at least in one European country
  • In phase III (in these trials the drug / treatment is tested in large groups of people, involving from several hundred to several thousand participants. These trials are conducted to provide stronger evidence of the effectiveness and safety of the new drug / treatment.)

How many Phase III trials are reported in the CTW?

The CTW reports currently 11 ongoing Phase III clinical trials recruiting participants in Europe. These trials are listened in the table below:

Study

Study sponsor

Name of the drug

Condition

COGNITE

AZTherapies

ALZT-OP1

Evidence of early Alzheimer's disease

GENERATION S1

Novartis

CAD106 and CNP520

Risk of developing Alzheimer's dementia

GENERATION S2

Novartis

CNP520

Risk of developing Alzheimer's dementia

GRADUATE 1 & GRADUATE 2

Hoffmann- La Roche

Gantenerumab

Prodromal to mild Alzheimer’s disease

HARMONY

ACADIA Pharmaceuticals Inc.

Pimavanserin

People with dementia-related psychosis

LUCIDITY

TauRx Therapeutics Ltd

TRx0237

Mild Alzheimer's disease 

MissionAD1 & MissionAD2

Eisai

Elenbecestat

Early Alzheimer's disease

SYMBAD

University of Sussex

Mirtazapine and Carbamazepine

Alzheimer's disease and agitated behaviours

17-AVP-786-305

Avanir Pharmaceuticals

AVP-786

Agitation in people with dementia of the Alzheimer's type

 

 
 

Last Updated: Thursday 07 February 2019

 

 
  • Acknowledgements

    Alzheimer Europe's Clinical Trial Watch received funding under an operating grant from the European Union’s Health Programme (2014–2020).
  • European Union
 
 

Options